GSK announces positive headline data from phase II seasonal influenza mRNA vaccine programme
GSK's mRNA seasonal flu vaccine showed positive immune responses in younger and older adults, supporting progression to phase III trials. The mRNA platform demonstrated strong antibody titres and acceptable safety profiles.
Related Clinical Trials
Highlighted Terms
Related News
GSK's mRNA seasonal flu vaccine showed positive immune responses in younger and older adults, supporting progression to phase III trials. The mRNA platform demonstrated strong antibody titres and acceptable safety profiles.
GSK announced positive phase II trial data for its mRNA seasonal flu vaccine, meeting success criteria in younger and older participants. The vaccine showed acceptable safety and reactogenicity. GSK plans to advance to late-stage clinical development. Stock is down 1.52% at $43.10.
Article sent to my@email.address. All fields required; separate multiple recipients with a semicolon. Active subscribers access full article; others directed to abstract.
GSK's phase II trial for mRNA seasonal flu vaccine met success criteria in both younger and older adults, showing acceptable safety and reactogenicity. The mRNA platform elicited strong antibody responses, prompting progression to late-stage development. GSK aims to create a best-in-class vaccine for greater flu protection.
GSK reports positive interim Phase II trial results for its mRNA-based multivalent influenza vaccine candidate, GSK4382276A, meeting pre-defined success criteria in both younger and older adult groups. The vaccine, encoding antigens matched to WHO-recommended influenza strains, showed potential for improved immune responses compared to current vaccines, prompting GSK to advance the programme into late-stage clinical development.
GSK's phase 2 data for its seasonal influenza mRNA vaccine, GSK4382276A, showed robust immune responses against A and B strains in older and younger adults, supporting progression to phase 3 trials. The vaccine demonstrated acceptable safety and reactogenicity profiles, aiming to develop a best-in-class vaccine for greater protection during flu season.
GSK’s mRNA flu vaccine succeeds against both strains in Phase 2.
GSK's mRNA seasonal flu vaccine shows strong immune responses and safety in phase II trial, supporting progression to phase III.
GSK's mRNA-based seasonal flu vaccine successfully completed phase II trials, showing positive immune responses and safety profiles, advancing to phase III. The company's full control over development and manufacturing from CureVac, along with AI/ML-based optimizations, strengthens its mRNA vaccine program. GSK's financial stability, with a market cap of $88.32B and a dividend yield of 3.46%, supports ongoing vaccine technology investments.
GSK announces positive phase II data for mRNA seasonal flu vaccine, showing strong immune responses and safety profile, supporting progression to phase III trials.